Context. - Clinical, epidemiologic, and policy considerations support updating the cost-effectiveness of pneumococcal vaccination for elderly people and targeting the evaluation only to prevention of pneumococcal bacteremia.
- To assess the implications for medical costs and health effects of vaccination against pneumococcal bacteremia in elderly people.
- Cost-effectiveness analysis of pneumococcal vaccination compared with no vaccination, from a societal perspective.
- The elderly population aged 65 years and older in the United States in 3 geographic areas :
and Monroe County,
- Incremental medical costs and health effects, expressed in quality-adjusted life-years per person vaccinated.
- Vaccination was cost saving, ie, it both reduced medical expenses and improved health, for all age groups and geographic areas analyzed in the base case.
For people aged 65 years and older, vaccination saved $8.27 and gained 1.21 quality-adjusted days of life per person vaccinated.
Vaccination of the 23 million elderly people unvaccinated in 1993 would have gained about 78 000 years of healthy life and saved $194 million.
In univariate sensitivity analysis, the results remained cost saving except for doubling vaccination costs, including future medical costs of survivors, and lowering vaccination effectiveness. (...)
Mots-clés Pascal : Pneumococcie, Streptococcie, Bactériose, Infection, Vaccination, Campagne de masse, Rapport coût bénéfice, Etude comparative, Vieillard, Homme, Bactériémie, Prévention, Immunoprophylaxie, Economie santé
Mots-clés Pascal anglais : Pneumococcal infection, Streptococcal infection, Bacteriosis, Infection, Vaccination, Mass campaign, Cost benefit ratio, Comparative study, Elderly, Human, Bacteremia, Prevention, Immunoprophylaxis, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0543129
Code Inist : 002B05A02. Création : 24/03/1998.